Vitrafy Life Sciences (VFY) Investor presentation summary

Foundational technology and market need

• Provides an integrated cryopreservation platform for biologics, targeting blood, animal reproduction, and cell & gene therapy markets.

• Addresses critical infrastructure replacement in the U.S. blood industry, with a 2027 deadline due to obsolete technology and chronic shortages.

• Validated by U.S. Army studies, achieving 94% post-thaw platelet recovery, exceeding regulatory standards.

• Commercial traction includes partnerships with Vitalant and IMV Technologies, enabling access to major U.S. blood networks and global animal reproduction markets.

• Platform is IP-protected, offering hardware, software, and consumables for recurring revenue.

Differentiated technology and scientific validation

• Delivers superior post-thaw quality and rapid processing, enabling decentralized and emergency use.

• Eliminates lab-bound wash steps, allowing deployment in ambulances, battlefields, and rural hospitals.

• Demonstrates high viability in T-cell preservation for cell & gene therapy, validated by third parties.

• Commercialized in animal reproduction, showing significant improvements in fertilization rates and year-on-year revenue growth.

• Technology is translatable from animal to human health applications.

Business model and growth strategy

• Operates a high-margin, recurring revenue model based on managed services and consumables.

• Embedded in customer workflows through hardware, cloud software, and single-use consumables.

• Prioritizes blood, animal reproduction, and cell & gene therapy as key verticals, with tailored go-to-market strategies.

• Partnerships with industry leaders and government bodies drive adoption and scale.

• Upcoming catalysts include FDA device registration, U.S. market expansion, and manufacturing scale-up.